FDA approves Fabhalta as oral treatment for paroxysmal nocturnal hemoglobinuria
The US Food and Drug Administration has approved Fabhalta (iptacopan) as first oral monotherapy for adults suffering from paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare and chronic blood disorder where red blood cells are prone to premature destruction by the complement system. Despite prior anti-C5 treatments, a good number of patients with PNH still […]